Cargando…
(-)-Oleocanthal Nutraceuticals for Alzheimer’s Disease Amyloid Pathology: Novel Oral Formulations, Therapeutic, and Molecular Insights in 5xFAD Transgenic Mice Model
Alzheimer’s disease (AD) is a complex progressive neurodegenerative disorder affecting humans mainly through the deposition of Aβ-amyloid (Aβ) fibrils and accumulation of neurofibrillary tangles in the brain. Currently available AD treatments only exhibit symptomatic relief but do not generally inte...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157389/ https://www.ncbi.nlm.nih.gov/pubmed/34069842 http://dx.doi.org/10.3390/nu13051702 |
_version_ | 1783699672869634048 |
---|---|
author | Tajmim, Afsana Cuevas-Ocampo, Areli K. Siddique, Abu Bakar Qusa, Mohammed H. King, Judy Ann Abdelwahed, Khaldoun S. Sonju, Jafrin Jobayer El Sayed, Khalid A. |
author_facet | Tajmim, Afsana Cuevas-Ocampo, Areli K. Siddique, Abu Bakar Qusa, Mohammed H. King, Judy Ann Abdelwahed, Khaldoun S. Sonju, Jafrin Jobayer El Sayed, Khalid A. |
author_sort | Tajmim, Afsana |
collection | PubMed |
description | Alzheimer’s disease (AD) is a complex progressive neurodegenerative disorder affecting humans mainly through the deposition of Aβ-amyloid (Aβ) fibrils and accumulation of neurofibrillary tangles in the brain. Currently available AD treatments only exhibit symptomatic relief but do not generally intervene with the amyloid and tau pathologies. The extra-virgin olive oil (EVOO) monophenolic secoiridoid S-(–)-oleocanthal (OC) showed anti-inflammatory activity through COX system inhibition with potency comparable to the standard non-steroidal anti-inflammatory drug (NSAID) like ibuprofen. OC also showed positive in vitro, in vivo, and clinical therapeutic effects against cardiovascular diseases, many malignancies, and AD. Due to its pungent, astringent, and irritant taste, OC should be formulated in acceptable dosage form before its oral use as a potential nutraceutical. The objective of this study is to develop new OC oral formulations, assess whether they maintained OC activity on the attenuation of β-amyloid pathology in a 5xFAD mouse model upon 4-month oral dosing use. Exploration of potential OC formulations underlying molecular mechanism is also within this study scope. OC powder formulation (OC-PF) and OC-solid dispersion formulation with erythritol (OC-SD) were prepared and characterized using FT-IR spectroscopy, powder X-ray diffraction, and scanning electron microscopy (ScEM) analyses. Both formulations showed an improved OC dissolution profile. OC-PF and OC-SD improved memory deficits of 5xFAD mice in behavioral studies. OC-PF and OC-SD exhibited significant attenuation of the accumulation of Aβ plaques and tau phosphorylation in the brain of 5xFAD female mice. Both formulations markedly suppressed C3AR1 (complement component 3a receptor 1) activity by targeting the downstream marker STAT3. Collectively, these results demonstrate the potential for the application of OC-PF as a prospective nutraceutical or dietary supplement to control the progression of amyloid pathogenesis associated with AD. |
format | Online Article Text |
id | pubmed-8157389 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81573892021-05-28 (-)-Oleocanthal Nutraceuticals for Alzheimer’s Disease Amyloid Pathology: Novel Oral Formulations, Therapeutic, and Molecular Insights in 5xFAD Transgenic Mice Model Tajmim, Afsana Cuevas-Ocampo, Areli K. Siddique, Abu Bakar Qusa, Mohammed H. King, Judy Ann Abdelwahed, Khaldoun S. Sonju, Jafrin Jobayer El Sayed, Khalid A. Nutrients Article Alzheimer’s disease (AD) is a complex progressive neurodegenerative disorder affecting humans mainly through the deposition of Aβ-amyloid (Aβ) fibrils and accumulation of neurofibrillary tangles in the brain. Currently available AD treatments only exhibit symptomatic relief but do not generally intervene with the amyloid and tau pathologies. The extra-virgin olive oil (EVOO) monophenolic secoiridoid S-(–)-oleocanthal (OC) showed anti-inflammatory activity through COX system inhibition with potency comparable to the standard non-steroidal anti-inflammatory drug (NSAID) like ibuprofen. OC also showed positive in vitro, in vivo, and clinical therapeutic effects against cardiovascular diseases, many malignancies, and AD. Due to its pungent, astringent, and irritant taste, OC should be formulated in acceptable dosage form before its oral use as a potential nutraceutical. The objective of this study is to develop new OC oral formulations, assess whether they maintained OC activity on the attenuation of β-amyloid pathology in a 5xFAD mouse model upon 4-month oral dosing use. Exploration of potential OC formulations underlying molecular mechanism is also within this study scope. OC powder formulation (OC-PF) and OC-solid dispersion formulation with erythritol (OC-SD) were prepared and characterized using FT-IR spectroscopy, powder X-ray diffraction, and scanning electron microscopy (ScEM) analyses. Both formulations showed an improved OC dissolution profile. OC-PF and OC-SD improved memory deficits of 5xFAD mice in behavioral studies. OC-PF and OC-SD exhibited significant attenuation of the accumulation of Aβ plaques and tau phosphorylation in the brain of 5xFAD female mice. Both formulations markedly suppressed C3AR1 (complement component 3a receptor 1) activity by targeting the downstream marker STAT3. Collectively, these results demonstrate the potential for the application of OC-PF as a prospective nutraceutical or dietary supplement to control the progression of amyloid pathogenesis associated with AD. MDPI 2021-05-18 /pmc/articles/PMC8157389/ /pubmed/34069842 http://dx.doi.org/10.3390/nu13051702 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tajmim, Afsana Cuevas-Ocampo, Areli K. Siddique, Abu Bakar Qusa, Mohammed H. King, Judy Ann Abdelwahed, Khaldoun S. Sonju, Jafrin Jobayer El Sayed, Khalid A. (-)-Oleocanthal Nutraceuticals for Alzheimer’s Disease Amyloid Pathology: Novel Oral Formulations, Therapeutic, and Molecular Insights in 5xFAD Transgenic Mice Model |
title | (-)-Oleocanthal Nutraceuticals for Alzheimer’s Disease Amyloid Pathology: Novel Oral Formulations, Therapeutic, and Molecular Insights in 5xFAD Transgenic Mice Model |
title_full | (-)-Oleocanthal Nutraceuticals for Alzheimer’s Disease Amyloid Pathology: Novel Oral Formulations, Therapeutic, and Molecular Insights in 5xFAD Transgenic Mice Model |
title_fullStr | (-)-Oleocanthal Nutraceuticals for Alzheimer’s Disease Amyloid Pathology: Novel Oral Formulations, Therapeutic, and Molecular Insights in 5xFAD Transgenic Mice Model |
title_full_unstemmed | (-)-Oleocanthal Nutraceuticals for Alzheimer’s Disease Amyloid Pathology: Novel Oral Formulations, Therapeutic, and Molecular Insights in 5xFAD Transgenic Mice Model |
title_short | (-)-Oleocanthal Nutraceuticals for Alzheimer’s Disease Amyloid Pathology: Novel Oral Formulations, Therapeutic, and Molecular Insights in 5xFAD Transgenic Mice Model |
title_sort | (-)-oleocanthal nutraceuticals for alzheimer’s disease amyloid pathology: novel oral formulations, therapeutic, and molecular insights in 5xfad transgenic mice model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157389/ https://www.ncbi.nlm.nih.gov/pubmed/34069842 http://dx.doi.org/10.3390/nu13051702 |
work_keys_str_mv | AT tajmimafsana oleocanthalnutraceuticalsforalzheimersdiseaseamyloidpathologynoveloralformulationstherapeuticandmolecularinsightsin5xfadtransgenicmicemodel AT cuevasocampoarelik oleocanthalnutraceuticalsforalzheimersdiseaseamyloidpathologynoveloralformulationstherapeuticandmolecularinsightsin5xfadtransgenicmicemodel AT siddiqueabubakar oleocanthalnutraceuticalsforalzheimersdiseaseamyloidpathologynoveloralformulationstherapeuticandmolecularinsightsin5xfadtransgenicmicemodel AT qusamohammedh oleocanthalnutraceuticalsforalzheimersdiseaseamyloidpathologynoveloralformulationstherapeuticandmolecularinsightsin5xfadtransgenicmicemodel AT kingjudyann oleocanthalnutraceuticalsforalzheimersdiseaseamyloidpathologynoveloralformulationstherapeuticandmolecularinsightsin5xfadtransgenicmicemodel AT abdelwahedkhaldouns oleocanthalnutraceuticalsforalzheimersdiseaseamyloidpathologynoveloralformulationstherapeuticandmolecularinsightsin5xfadtransgenicmicemodel AT sonjujafrinjobayer oleocanthalnutraceuticalsforalzheimersdiseaseamyloidpathologynoveloralformulationstherapeuticandmolecularinsightsin5xfadtransgenicmicemodel AT elsayedkhalida oleocanthalnutraceuticalsforalzheimersdiseaseamyloidpathologynoveloralformulationstherapeuticandmolecularinsightsin5xfadtransgenicmicemodel |